Positron emission tomography, commonly known as PET, is a nuclear medicine imaging technique used to evaluate metabolic activity within tissues. It is especially valuable in oncology because many malignant cells use glucose at a higher rate than surrounding normal tissues.
In thoracic imaging, PET is often combined with computed tomography to form PET-CT, which merges metabolic information with detailed anatomy.
This combination is particularly useful for evaluating pulmonary nodules, staging lung cancer, identifying metastatic disease, and helping guide biopsy and treatment decisions.
What Is Positron Emission Tomography?
Positron emission tomography is an imaging technique that evaluates how tissues function rather than simply showing their structure. Traditional imaging methods, such as chest radiography and CT, primarily provide anatomical information. They show the size, shape, location, density, and structural appearance of organs and abnormalities.
PET imaging adds a different type of information by demonstrating metabolic activity. Tissues that are more metabolically active may take up greater amounts of a radioactive tracer and appear more prominent on the resulting images.
This functional information can be particularly helpful when evaluating suspected malignancy because many cancer cells have increased metabolic activity. However, increased metabolic activity is not unique to cancer. Inflammation, infection, and other active disease processes may also produce abnormal tracer uptake. For this reason, PET findings must always be interpreted within the broader clinical picture.
How PET Imaging Works
PET imaging requires the administration of a small amount of radioactive material called a radiotracer. The radiotracer travels through the bloodstream and accumulates in tissues according to their metabolic activity.
The PET scanner detects radiation emitted by the tracer and uses this information to generate images that show areas of increased or decreased uptake.
The distribution of the tracer can provide information about how actively certain tissues are functioning. Areas with high metabolic activity may appear more prominent, while areas with lower metabolic activity may demonstrate less uptake.
In cancer imaging, the goal is often to identify tissues with unusually high glucose metabolism that may represent malignant cells.
Fluorodeoxyglucose and PET Imaging
One of the most commonly used radiotracers in PET imaging is fluorodeoxyglucose, or FDG. FDG is a radioactive glucose analogue that behaves similarly to glucose after being introduced into the body.
Cells require glucose as an energy source. Tissues with high metabolic activity generally consume more glucose than less active tissues. Because many cancer cells have elevated metabolic demands, they frequently absorb larger amounts of FDG.
Once FDG enters metabolically active cells, it becomes trapped long enough for the PET scanner to detect its distribution. Areas with increased FDG uptake may therefore raise suspicion for malignancy.
However, FDG uptake is not specific to cancer. Any tissue with increased glucose metabolism can potentially show increased activity on PET imaging.
This includes tissues affected by:
- Infection
- Inflammation
- Healing
- Certain benign tumors
- Granulomatous disease
- Some physiologic processes
Note: This limitation is an important reason PET cannot independently confirm a diagnosis of cancer.
PET-CT
PET imaging is commonly combined with computed tomography in a single examination known as PET-CT. The two techniques provide complementary information. PET demonstrates metabolic activity, while CT provides detailed information about anatomy.
The CT portion of the study can show:
- Size of a lesion
- Shape of a lesion
- Exact location
- Tissue density
- Relationship to nearby structures
- Lymph-node enlargement
- Other structural abnormalities
The PET portion demonstrates whether tissues have increased or decreased metabolic activity. When the two image sets are combined, clinicians can determine exactly where abnormal metabolic activity is occurring.
For example, PET may reveal an area of increased FDG uptake in the chest. CT can then determine whether that activity corresponds to a pulmonary nodule, enlarged lymph node, chest wall abnormality, or another structure. This fusion of functional and anatomical information makes PET-CT particularly useful in thoracic oncology.
PET Compared With CT
PET and CT are not competing techniques. They answer different clinical questions. A CT scan is primarily an anatomical study. It can show a pulmonary nodule in considerable detail, including its size, borders, internal density, calcification, and relationship to nearby structures. PET evaluates the metabolic behavior of the tissue.
A CT scan may identify a 2 cm pulmonary nodule, but its structural appearance may not clearly indicate whether it is benign or malignant. PET can provide additional information by showing whether that nodule demonstrates increased FDG uptake.
In this way, CT answers the question, “What does the abnormality look like?” while PET helps answer, “How metabolically active is the abnormality?” Combining the two can improve diagnostic evaluation.
PET in Thoracic Imaging
PET is particularly important in thoracic imaging because the lungs are a common site of both primary and metastatic cancer.
It may be used to evaluate:
- Pulmonary nodules
- Suspected lung cancer
- Known lung cancer
- Mediastinal lymph nodes
- Hilar lymph nodes
- Possible metastatic disease
- Response to certain cancer treatments
Note: One of the most common uses is the evaluation of a pulmonary lesion that cannot be confidently classified using CT findings alone.
PET and Solitary Pulmonary Nodules
A solitary pulmonary nodule is a relatively small area of abnormal lung tissue surrounded by aerated lung. It is generally defined as a pulmonary opacity measuring less than 3 cm in diameter. Pulmonary nodules are common findings on chest imaging.
Many are benign and may result from previous infections, scar tissue, inflammatory conditions, granulomas, or other nonmalignant processes. However, some pulmonary nodules represent early lung cancer. The challenge is determining which nodules require further testing.
CT is usually the primary imaging method for characterizing pulmonary nodules because it can provide detailed information about their structural features.
CT Characteristics of Pulmonary Nodules
Several imaging characteristics can help estimate the likelihood that a pulmonary nodule is benign or malignant.
These include:
- Size
- Shape
- Border appearance
- Internal density
- Calcification pattern
- Presence of fat
- Growth over time
A smoothly marginated, spherical nodule may be more likely to represent a benign process. In contrast, an irregular, lobulated, or spiculated nodule raises greater concern for malignancy.
Calcification can also provide useful information. Certain patterns of calcification are more often associated with benign disease, while others may occur with malignancy.
Central or lamellar calcification tends to favor a benign lesion. Eccentric, speckled, or amorphous calcification may be more suspicious. Although these characteristics can help estimate risk, they do not always provide a definitive answer. This is where PET may be useful.
How PET Helps Evaluate Pulmonary Nodules
PET adds metabolic information to the anatomical findings obtained from CT. A pulmonary nodule with increased FDG uptake is considered metabolically active. In the appropriate clinical setting, this finding increases suspicion for malignancy. A nodule without significant uptake may be less suspicious.
PET is especially useful when the probability of malignancy is considered intermediate after the patient’s risk factors and CT findings are evaluated. If the probability of malignancy is very low, clinicians may choose serial CT imaging rather than PET or biopsy.
If the probability is already very high and the lesion appears surgically resectable, proceeding directly toward surgical evaluation may be appropriate in selected patients. PET is particularly helpful when the initial probability falls somewhere between these extremes.
Nodule Size and PET Accuracy
The size of a pulmonary nodule significantly affects the usefulness of PET imaging. PET tends to be more accurate for larger lesions. Pulmonary nodules around 1 cm or greater are generally more suitable for metabolic evaluation than very small nodules.
Very small lesions may not contain enough metabolically active tissue for the scanner to detect abnormal FDG uptake reliably. This means that a malignant lesion smaller than approximately 10 mm may appear PET-negative.
A negative PET scan in a small nodule should therefore not automatically be interpreted as proof that the lesion is benign.
Other factors must still be considered, including:
- Nodule appearance on CT
- Growth over time
- Smoking history
- Age
- Previous cancer history
- Clinical symptoms
- Environmental or occupational exposures
Note: PET is one component of the evaluation rather than a substitute for clinical judgment.
False-Positive PET Findings
One of the most important limitations of PET imaging is the possibility of false-positive results. A false-positive result occurs when increased FDG uptake is present even though the abnormality is not malignant.
The primary reason this occurs is that FDG reflects glucose metabolism rather than cancer itself. Inflammatory and infectious processes can have high metabolic activity and therefore absorb significant amounts of FDG.
Examples include:
- Pneumonia
- Fungal infections
- Granulomatous disease
- Active inflammation
- Healing tissues
Note: Histoplasmosis is one example of an infectious process that may produce FDG-avid pulmonary nodules or lymph nodes. These findings can mimic malignancy on PET imaging. Therefore, an area of increased FDG uptake should be considered suspicious but not diagnostic of cancer.
False-Negative PET Findings
PET can also produce false-negative results. A false-negative result occurs when a malignant lesion does not demonstrate significant FDG uptake. This may occur for several reasons. The lesion may simply be too small for PET to detect reliably.
Some malignancies also have relatively low metabolic activity. Examples can include certain slow-growing adenocarcinomas, adenocarcinoma in situ, and carcinoid tumors. These tumors may not accumulate enough FDG to appear clearly abnormal.
As a result, a negative PET scan cannot completely exclude malignancy. This is especially important when CT imaging or clinical risk factors remain concerning.
Sensitivity and Specificity
PET is a valuable test, but it is not perfectly accurate. In the evaluation of suspected lung cancer, PET has been described as having a sensitivity of approximately 89% and a specificity of approximately 78%.
Sensitivity refers to the ability of the test to correctly identify patients who have the disease. Specificity refers to the ability of the test to correctly identify patients who do not have the disease.
A sensitivity below 100% means some cancers may be missed. A specificity below 100% means some benign abnormalities may appear suspicious. These limitations demonstrate why PET findings must be interpreted together with other diagnostic information.
PET Does Not Replace Tissue Diagnosis
PET can increase or decrease suspicion for malignancy, but it generally cannot provide a definitive diagnosis. The diagnosis of lung cancer usually requires a tissue specimen. Tissue allows pathologists to directly examine cells and determine whether malignancy is present.
It may also allow clinicians to identify the specific type of cancer. Biopsy options depend on the location and characteristics of the lesion.
Common methods include:
- Flexible bronchoscopy
- Endobronchial ultrasound
- Transthoracic needle biopsy
- Surgical biopsy
Note: PET can help determine where tissue sampling may be most useful, but it does not replace histologic confirmation.
Flexible Bronchoscopy
Flexible bronchoscopy is commonly used to evaluate suspected lung cancer, particularly when lesions are located near or within the central airways. A bronchoscope is passed through the airway, allowing direct visualization of the tracheobronchial tree.
Several sampling techniques may be used during the procedure, including:
- Bronchial washings
- Brushings
- Forceps biopsy
- Needle aspiration
- Bronchoalveolar lavage
Note: Bronchoscopy may also help evaluate suspicious lymph nodes when combined with additional technologies.
Endobronchial Ultrasound
Endobronchial ultrasound, commonly called EBUS, allows ultrasound imaging to be performed from within the airways. This technique is particularly useful for evaluating hilar and mediastinal lymph nodes.
A needle can be guided through the airway wall into a suspicious lymph node while ultrasound is used to visualize the target.
PET may identify a metabolically active lymph node, and EBUS can then be used to obtain tissue from that area. This relationship illustrates how imaging and tissue sampling work together during lung cancer evaluation.
Transthoracic Needle Biopsy
Transthoracic needle biopsy is another method for obtaining tissue from pulmonary lesions. During this procedure, a needle is passed through the chest wall and into the abnormality.
CT or another imaging technique is typically used to guide placement of the needle.
This approach is often useful for peripheral pulmonary lesions that may be difficult to reach with bronchoscopy. The tissue obtained can then be examined for evidence of malignancy.
PET and Lung Cancer Staging
PET plays an important role after lung cancer has been diagnosed or is strongly suspected. At this stage, the goal is no longer limited to determining whether the primary lesion may be malignant.
Clinicians also need to determine how far the cancer has spread. This process is called staging. Staging is critical because it influences prognosis and treatment selection.
A tumor confined to one location may be treated very differently from cancer that has spread to regional lymph nodes or distant organs. PET-CT can help identify areas of metabolically active disease throughout the body.
The TNM System
Non-small cell lung cancer is commonly staged using the TNM system.
The three major components are:
- T for primary tumor
- N for regional lymph nodes
- M for distant metastasis
The T component describes the size and local extent of the primary tumor. The N component describes whether cancer has spread to regional lymph nodes. The M component describes whether distant metastatic disease is present.
PET-CT is particularly useful when evaluating the N and M components.
PET and Lymph-Node Assessment
Lung cancer commonly spreads through lymphatic pathways. Determining whether hilar or mediastinal lymph nodes are involved can significantly affect staging and treatment.
CT may identify enlarged lymph nodes, but size alone cannot determine whether a node contains malignant cells. Some enlarged lymph nodes are reactive and benign. Conversely, some cancerous lymph nodes may not be significantly enlarged.
PET adds metabolic information. A lymph node with increased FDG uptake may be suspicious for metastatic involvement. However, inflammatory lymph nodes can also demonstrate increased FDG uptake.
This means PET-positive lymph nodes frequently require tissue confirmation before treatment decisions are made.
Confirming Mediastinal Lymph-Node Involvement
Several techniques may be used to evaluate suspicious mediastinal lymph nodes. Bronchoscopy with transbronchial needle aspiration can obtain samples from selected lymph-node locations.
Endobronchial ultrasound can improve the ability to identify and sample specific nodes. Endoscopic ultrasound may also be useful for certain lymph-node stations.
If imaging suggests lymph-node involvement but bronchoscopic techniques do not provide a diagnosis, surgical staging may be necessary.
Possible procedures include:
- Mediastinoscopy
- Mediastinotomy
- Thoracoscopy
Note: In patients undergoing potentially curative surgery, mediastinal lymph-node dissection may provide definitive pathologic staging.
PET and Distant Metastatic Disease
PET-CT is also valuable for identifying possible metastatic disease beyond the chest.
Lung cancer may spread to several organs, including the:
- Liver
- Adrenal glands
- Bones
- Distant lymph nodes
- Other tissues
Whole-body PET imaging can reveal metabolically active abnormalities that may not have been suspected based on symptoms alone. Detecting distant metastases can substantially alter treatment planning.
For example, a patient who appears to have localized lung cancer on chest CT may be found to have metabolically active lesions elsewhere in the body on PET. If these lesions are confirmed as metastatic disease, surgery may no longer be the preferred treatment approach.
PET and Brain Metastases
PET is useful for many aspects of cancer staging, but brain imaging is usually performed separately. CT or MRI of the brain may be ordered when symptoms suggest possible metastatic disease or when more advanced lung cancer is being evaluated.
MRI is often preferred because it is more sensitive for detecting brain metastases. PET is therefore part of a broader staging strategy rather than the only imaging examination required.
PET in Treatment Planning
The information obtained from PET-CT can directly influence treatment decisions. For example, PET may help determine whether a patient should undergo:
- Surgery
- Radiation therapy
- Chemotherapy
- A combination of therapies
- Additional biopsy
- Continued imaging surveillance
A lesion that appears localized may be approached differently from disease involving multiple lymph nodes or distant organs. PET can also help identify which abnormality may be most appropriate for biopsy.
If several suspicious sites are present, clinicians may choose the location that provides the safest and most useful tissue sample.
PET and Radiation Therapy
PET-CT can also contribute to radiation treatment planning. Radiation therapy must be directed toward areas containing known or suspected tumor while minimizing exposure to surrounding healthy tissues.
The CT portion of PET-CT provides anatomical localization, while PET may help identify metabolically active portions of disease.
This combination may assist clinicians in defining treatment regions. However, PET findings must be interpreted carefully because inflammation can also produce increased tracer uptake.
Patient Preparation for PET Imaging
Patient preparation is important because FDG behaves similarly to glucose. Blood glucose levels and recent food intake can influence tracer distribution. Patients are commonly instructed to avoid eating for a period before the examination, depending on the imaging facility’s protocol.
After FDG is administered, time is allowed for the tracer to circulate and accumulate within tissues. Patients are generally encouraged to remain relatively quiet during this uptake period.
Muscular activity can increase glucose metabolism and produce tracer uptake in skeletal muscle, potentially affecting image interpretation.
During the scan itself, the patient lies on a table that moves through the scanner. Remaining still helps reduce motion and improve image quality.
Radiation Exposure
PET-CT involves exposure to ionizing radiation. Radiation comes from both the radioactive tracer and the CT portion of the examination. The amount of radiation is controlled to provide diagnostically useful images while limiting unnecessary exposure.
As with other imaging procedures involving radiation, clinicians weigh the potential diagnostic benefit against the risks. This consideration becomes especially important when repeated imaging studies are required.
In patients being evaluated for serious conditions such as lung cancer, the information obtained from PET-CT may provide substantial clinical benefit.
Advantages of PET-CT
PET-CT offers several important advantages in thoracic oncology. It combines functional and anatomical information in a single examination. PET can identify metabolic abnormalities that may not be obvious based on size or appearance alone.
CT provides the precise anatomical detail needed to determine where those abnormalities are located. PET-CT can also evaluate multiple regions of the body during the same examination. This makes it useful for assessing both the primary tumor and potential metastatic disease.
Another major advantage is its ability to influence further diagnostic testing. PET may help determine whether a pulmonary nodule requires biopsy, whether a lymph node should be sampled, or whether distant lesions need additional evaluation.
Limitations of PET-CT
Despite its usefulness, PET-CT has several important limitations.
- FDG uptake is not specific to malignancy. Inflammation and infection can produce false-positive results.
- Some cancers have relatively low metabolic activity and may produce false-negative results.
- Small lesions may not be reliably detected.
- PET does not provide the microscopic information needed to determine the exact type of tumor.
- Additional limitations include radiation exposure, the need for specialized equipment, and the requirement for careful patient preparation.
Note: These limitations reinforce the importance of using PET as part of a complete diagnostic evaluation rather than as an isolated test.
Interpreting PET Results
PET findings should be interpreted alongside the patient’s entire clinical picture.
Clinicians consider factors such as:
- Patient age
- Smoking history
- Previous malignancy
- Symptoms
- CT appearance
- Lesion size
- Growth over time
- Laboratory findings
- Infection risk
- Biopsy results
A highly metabolically active pulmonary nodule in a patient with significant lung cancer risk factors may be very concerning. The same pattern of uptake in a patient with an active pulmonary infection may have a different interpretation.
Similarly, a PET-negative nodule should not automatically be dismissed if it has suspicious CT features or has demonstrated growth. Clinical context remains essential.
PET and Serial Imaging
Not every pulmonary nodule requires immediate biopsy or surgery. Some lesions may be followed with serial CT imaging. This is particularly true when the nodule is small, has low-risk imaging characteristics, or occurs in a patient with a low overall probability of malignancy.
Monitoring allows clinicians to determine whether the lesion grows or changes over time. Malignant nodules often demonstrate progressive growth, while many benign lesions remain stable.
PET may be added when the level of suspicion increases or when additional metabolic information could alter management. The decision between surveillance, PET, biopsy, and surgery depends on the overall risk profile rather than a single imaging finding.
PET as Part of a Multimodal Evaluation
The strongest use of PET occurs when it is combined with other diagnostic information. Chest radiography may first identify an abnormality. CT can then characterize the lesion in greater detail.
PET can evaluate metabolic activity. Bronchoscopy or needle biopsy can provide tissue. Pathology can establish the final diagnosis.
Additional imaging can determine the extent of disease. Each method contributes different information. No single test answers every question. PET is therefore most effective when used as part of a coordinated diagnostic and staging process.
Why PET Is Important in Lung Cancer Care
Lung cancer management depends heavily on accurate diagnosis and staging. A suspicious lesion must first be distinguished from benign disease as accurately as possible. If cancer is confirmed, clinicians must determine whether it remains localized or has spread. PET-CT supports both of these goals.
It can increase suspicion for malignancy in a pulmonary lesion, identify metabolically active lymph nodes, detect possible distant metastases, and guide decisions about where tissue should be obtained.
It may also prevent unnecessary procedures when imaging reveals disease that would make a planned surgical approach inappropriate. At the same time, PET findings must be confirmed when they have major treatment implications.
PET Scan Practice Questions
1. What is positron emission tomography (PET)?
A nuclear medicine imaging technique that evaluates metabolic and physiologic activity within tissues.
2. What type of information does PET primarily provide?
Information about the metabolic activity and function of tissues.
3. What imaging technique is commonly combined with PET in thoracic imaging?
Computed tomography (CT)
4. What is the primary advantage of combining PET with CT?
PET provides metabolic information while CT provides detailed anatomical information, allowing abnormal activity to be precisely localized.
5. What radioactive tracer is commonly used for PET imaging when evaluating suspected cancer?
Fluorodeoxyglucose (FDG)
6. What is fluorodeoxyglucose (FDG)?
A radioactive glucose analogue used to identify tissues with increased glucose metabolism.
7. Why do many malignant cells demonstrate increased FDG uptake?
Malignant cells often have increased metabolic activity and consume glucose at a higher rate than surrounding normal tissues.
8. What does increased FDG uptake in a pulmonary lesion suggest?
It suggests increased metabolic activity and may raise suspicion for malignancy.
9. Why does increased FDG uptake not definitively diagnose cancer?
Infection, inflammation, and other nonmalignant processes can also have increased metabolic activity and take up FDG.
10. What is a solitary pulmonary nodule?
A parenchymal lung opacity measuring less than 3 cm in diameter that is surrounded by aerated lung.
11. What CT border characteristic of a pulmonary nodule increases suspicion for malignancy?
An irregular, lobulated, or spiculated border.
12. What pulmonary nodule appearance is more commonly associated with a benign process?
A smoothly marginated, spherical appearance.
13. What type of pulmonary nodule calcification generally favors a benign process?
Central or lamellar calcification.
14. What calcification patterns in a pulmonary nodule may increase concern for malignancy?
Eccentric, speckled, or amorphous calcification.
15. When is PET particularly useful in the evaluation of a pulmonary nodule?
When the clinical and imaging findings indicate an intermediate probability of malignancy.
16. Why is PET less reliable for pulmonary nodules smaller than approximately 1 cm?
Very small lesions may be below the effective spatial resolution of PET and may not demonstrate detectable FDG uptake.
17. Can a PET-negative pulmonary nodule still be malignant?
Yes. Small lesions and certain slow-growing cancers may demonstrate little or no FDG uptake.
18. What is a false-positive PET result?
A finding in which increased FDG uptake suggests malignancy even though the abnormality is caused by a nonmalignant process.
19. What pulmonary conditions can produce false-positive PET findings?
Infections, pneumonia, inflammatory disease, and granulomatous conditions such as histoplasmosis.
20. What types of malignancies may produce false-negative PET findings because of relatively low metabolic activity?
Some adenocarcinomas, adenocarcinoma in situ, and carcinoid tumors.
21. What is the approximate sensitivity of PET for evaluating suspected lung cancer?
Approximately 89%.
22. What is the approximate specificity of PET for evaluating suspected lung cancer?
Approximately 78%.
23. Why is tissue confirmation often required when lung cancer is suspected despite PET findings?
PET cannot definitively distinguish malignant tissue from all benign infectious or inflammatory processes, so examination of tissue is generally required for a definitive diagnosis.
24. What are two commonly used nonsurgical methods for obtaining tissue from a suspected pulmonary malignancy?
Flexible bronchoscopy and transthoracic needle biopsy.
25. What components of the TNM lung cancer staging system are PET-CT particularly useful for evaluating?
The N component, which describes regional lymph-node involvement, and the M component, which describes distant metastatic disease.
26. What is the primary role of the CT portion of a PET-CT scan?
To provide detailed anatomical information about the size, shape, density, and location of abnormalities.
27. What is the primary role of the PET portion of a PET-CT scan?
To show the metabolic activity of tissues based on radiotracer uptake.
28. Why can PET-CT be more informative than PET or CT alone?
It combines functional metabolic information with precise anatomical localization.
29. What may be considered when a pulmonary nodule has a very low probability of malignancy?
Serial imaging may be used to monitor the lesion for growth or change over time.
30. What may be considered when a pulmonary lesion has a very high probability of malignancy and appears surgically resectable?
Proceeding directly toward surgical evaluation or resection may be reasonable in selected patients.
31. What feature of a pulmonary nodule is especially important when comparing current and previous imaging studies?
Whether the nodule has increased in size over time.
32. Why can pneumonia produce increased FDG uptake on PET?
Inflammatory cells in infected lung tissue may have increased glucose metabolism.
33. Why can histoplasmosis mimic lung cancer on PET imaging?
Granulomatous inflammation caused by the infection may produce increased FDG uptake.
34. What does PET contribute to lung cancer staging beyond evaluation of the primary tumor?
It can help identify metabolically active lymph nodes and possible distant metastatic disease.
35. In the TNM staging system, what does the T component represent?
The characteristics, size, and local extent of the primary tumor.
36. In the TNM staging system, what does the N component represent?
The presence and extent of regional lymph-node involvement.
37. In the TNM staging system, what does the M component represent?
The presence or absence of distant metastatic disease.
38. Why can CT alone be limited when evaluating lymph nodes for cancer?
Lymph-node size does not always indicate whether malignant cells are present.
39. Why can a normal-sized lymph node still be clinically important in lung cancer?
It may contain metastatic cancer even if it is not enlarged on CT.
40. Why does a PET-positive mediastinal lymph node often require biopsy?
Inflammation or infection can also cause increased FDG uptake in lymph nodes.
41. What procedure can be used to sample hilar or mediastinal lymph nodes through the airways?
Endobronchial ultrasound-guided needle sampling.
42. What is the advantage of endobronchial ultrasound during lymph-node biopsy?
It allows real-time visualization and guidance of the needle into selected lymph nodes.
43. When might mediastinoscopy be considered in lung cancer staging?
When mediastinal lymph-node involvement remains suspected and less invasive sampling is inconclusive or negative.
44. What is the purpose of mediastinal lymph-node dissection during lung cancer surgery?
To provide pathologic evaluation of lymph nodes and help establish the definitive stage.
45. Why is PET useful for evaluating possible distant metastases?
It can survey much of the body for areas of abnormal metabolic activity in a single examination.
46. What abdominal organs are commonly evaluated during lung cancer staging because they may contain metastatic disease?
The liver and adrenal glands.
47. What imaging study is often preferred for detecting brain metastases from lung cancer?
Magnetic resonance imaging (MRI) of the brain.
48. Why is PET generally not relied upon as the primary test for detecting brain metastases?
Dedicated brain imaging with CT or MRI, especially MRI, is more appropriate and sensitive for this purpose.
49. How can PET findings influence the decision to perform surgery for lung cancer?
Detection of lymph-node or distant metastatic disease may change whether surgical resection is appropriate.
50. How can PET help guide biopsy planning?
It can identify metabolically active areas that may be appropriate targets for obtaining tissue.
51. What does the term “metabolically active” mean on a PET scan?
It means that a tissue is taking up more radiotracer because of increased metabolic activity.
52. Why must PET findings be interpreted together with clinical history?
Because abnormal tracer uptake can result from both malignant and nonmalignant conditions.
53. What patient factor can increase concern that a pulmonary nodule is malignant?
A significant smoking history.
54. What previous medical history can raise suspicion when evaluating a pulmonary nodule?
A prior history of cancer.
55. Why are occupational and environmental exposures considered when evaluating a pulmonary nodule?
Certain exposures can increase the risk of lung disease and malignancy.
56. What role does lesion density play in the evaluation of a pulmonary nodule?
Density can provide structural clues that help estimate whether the lesion is more likely benign or malignant.
57. Why is the presence of fat within a pulmonary nodule useful on CT?
Fat can support a benign diagnosis in some pulmonary nodules.
58. What may happen if skeletal muscles are very active before or during FDG uptake?
The muscles may take up more FDG and interfere with image interpretation.
59. Why are patients usually encouraged to remain relatively quiet after receiving FDG?
To reduce unnecessary muscular glucose uptake that could affect PET images.
60. Why can recent food intake affect PET imaging?
Because blood glucose and insulin levels can influence FDG distribution and uptake.
61. Why is patient preparation important before a PET scan?
Proper preparation helps improve the accuracy and interpretability of radiotracer uptake.
62. What must a patient do during the actual PET scan to help produce clear images?
Remain relatively still.
63. What are the two main sources of radiation exposure during a PET-CT examination?
The radioactive tracer and the CT portion of the study.
64. Why must the benefits of PET-CT be weighed against radiation exposure?
Because the examination uses ionizing radiation, especially when repeated studies are considered.
65. How does PET differ fundamentally from a standard chest X-ray?
PET evaluates metabolic function, while chest radiography primarily shows anatomy and structural abnormalities.
66. How does PET differ fundamentally from CT?
PET emphasizes tissue metabolism, while CT emphasizes detailed anatomy.
67. What can PET reveal that may not be obvious from lesion size alone?
Whether the tissue is metabolically active.
68. Why can a structurally suspicious lesion still need PET evaluation?
PET may provide additional metabolic information that changes the estimated probability of malignancy.
69. Why can a metabolically inactive lesion still require follow-up?
Some cancers are small or slow-growing and may not demonstrate significant FDG uptake.
70. What is one reason PET may help prevent an unnecessary operation?
It may reveal distant metastatic disease that changes the treatment plan.
71. How can PET assist with radiation therapy planning?
It can help identify metabolically active areas that may need to be included in the treatment field.
72. Why must PET findings used for radiation planning be interpreted carefully?
Inflammation can also produce increased FDG uptake and mimic tumor activity.
73. What is the purpose of serial CT imaging in selected pulmonary nodules?
To monitor for growth or other changes over time.
74. What finding during serial imaging would generally increase concern for malignancy?
Progressive growth of the pulmonary nodule.
75. Why is PET considered part of a multimodal diagnostic approach?
Because it provides metabolic information that must be combined with anatomical imaging, clinical assessment, and tissue diagnosis when needed.
76. What does increased FDG uptake represent on PET imaging?
It represents increased glucose metabolism within the tissue.
77. Why are metabolically active cancer cells more likely to appear prominently on PET?
They often consume more glucose than surrounding normal cells.
78. What happens to FDG after it is taken up by metabolically active cells?
It becomes trapped within the cells long enough to be detected by the PET scanner.
79. Why can PET help localize disease when combined with CT?
CT shows the exact anatomical structure corresponding to the area of abnormal metabolic activity.
80. What is one limitation of using PET to evaluate ground-glass pulmonary nodules?
Some ground-glass lesions may have low metabolic activity and may not show significant FDG uptake.
81. Why should a negative PET scan not override suspicious CT findings?
Because some malignant lesions may be too small or too metabolically inactive to produce a positive PET result.
82. What is one reason a pulmonary nodule may be monitored rather than biopsied immediately?
Its overall probability of malignancy may be low based on clinical and imaging features.
83. What can bronchoscopy provide in addition to direct airway visualization?
It can obtain tissue and cellular samples through washings, brushings, needle aspiration, and forceps biopsy.
84. When is transthoracic needle biopsy especially useful?
When a pulmonary lesion is peripheral and difficult to reach with bronchoscopy.
85. What guidance is commonly used during transthoracic needle biopsy?
Imaging guidance, often with CT.
86. Why might surgical biopsy be required after nonsurgical testing?
Bronchoscopy or needle biopsy may fail to obtain an adequate or diagnostic tissue sample.
87. What is the main goal of cancer staging?
To determine the extent of disease spread.
88. Why is accurate lung cancer staging important?
It helps determine prognosis and guides treatment selection.
89. What does a PET-positive distant lesion potentially indicate in a patient with lung cancer?
Possible metastatic disease.
90. Why might a distant PET-positive lesion require additional evaluation?
Because increased FDG uptake can also result from benign inflammatory or infectious processes.
91. How can PET findings affect chemotherapy decisions?
Evidence of more widespread disease may support the use of systemic treatment rather than a purely local treatment approach.
92. How can PET findings affect radiation therapy decisions?
They may help identify the extent and location of metabolically active disease that requires treatment.
93. Why can PET be useful before a planned lung cancer surgery?
It may identify previously unsuspected lymph-node involvement or distant metastatic disease.
94. What is the definitive way to establish the pathologic stage of resected lung cancer?
Examination of the surgically removed tumor and lymph nodes.
95. Why can an enlarged lymph node on CT be benign?
Reactive inflammation or infection can cause lymph-node enlargement without cancer.
96. Why can a nonenlarged lymph node still contain malignancy?
Metastatic cancer can be present before the node becomes significantly enlarged.
97. What does whole-body PET assessment help clinicians evaluate?
Whether metabolically active disease may be present outside the primary tumor region.
98. Why is PET considered complementary rather than definitive?
It adds valuable metabolic information but cannot independently confirm or exclude malignancy in every case.
99. What types of information should be combined with PET findings when evaluating suspected lung cancer?
Clinical history, physical examination, CT findings, laboratory data, previous imaging, and tissue biopsy when necessary.
100. What is the overall role of PET-CT in thoracic oncology?
To help characterize suspicious lesions, evaluate lymph-node involvement, identify possible metastatic disease, and support diagnosis, staging, and treatment planning.
Final Thoughts
Positron emission tomography provides valuable information about metabolic activity within tissues and is especially useful when evaluating suspected or known lung cancer. When combined with CT, PET-CT allows metabolic abnormalities to be matched with detailed anatomical structures.
It can help characterize pulmonary nodules, assess lymph nodes, identify possible metastatic disease, and guide biopsy and treatment planning. However, PET is not definitive because infection and inflammation may cause increased FDG uptake, while small or slow-growing cancers may show little activity.
PET findings should therefore be interpreted alongside CT imaging, clinical risk factors, previous studies, and tissue diagnosis when necessary.
Written by:
John Landry is a registered respiratory therapist from Memphis, TN, and has a bachelor's degree in kinesiology. He enjoys using evidence-based research to help others breathe easier and live a healthier life.
References
- Kapoor M, Heston TF, Kasi A. PET Scanning. [Updated 2025 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
